The Impact of Mass Drug Administration on Lymphatic Filariasis

Table 4

Percentage antigenic prevalence reduction at mid-term and pre-TAS compared to baseline prevalence in LF mass drug administration.

Reference, country	Baseline antigen prevalence (N)	LF antigen prevalence (N); % antigen PR
		Mid-term	Pre-TAS
[14], Mali	21.42 (1139)	—	0 (760); 100.00
[15], American Samoa	16.00 (3018)	—	2.29 (1881); 85.69
[16], Egypt	19.00 (1000)	—	2.70 (1000); 85.79
[20], Egypt	32.61 (1877)	—	7.88 (1828); 75.84
[19], Nigeria	21.61 (2439)	—	7.38 (1720); 65.85
[23], Tanzania	23.65 (888)	10.60 (953); 51.18	—
[26], Indonesia	6.51 (722)	1.15 (871); 82.33	—
[27], Papua New Guinea	47.49 (558)	17.13 (543); 63.93	—

LF: lymphatic filariasis; N: sample size; pre-TAS, pretransmission assessment survey; % antigen PR, percentage antigen prevalence reduction compared to baseline antigen prevalence; —: no data available.